Fullmakt / proxy for Annual General Meeting
See attached documents
Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
Press release
Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
CAMBRIDGE, UK; GOTHENBURG, Sweden – 29 November 2023 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.
This
Årsredovisning OnDosis samt villkor bilaga A / Annual report OnDosis and terms appendix A
Årsredovisning OnDosis samt villkor bilaga A / Annual report OnDosis and terms appendix A
Årsredovisning / Annual report OnDosis AB
Årsredovisning 2022 / Annual report 2022 OnDosis AB
Fullständiga villkor Bilaga A
VILLKOR FÖR TECKNINGSOPTIONER SERIE 2023:A I ONDOSIS AB TERMS AND CONDITIONS FOR WARRANTS SERIES 2023:A IN ONDOSIS AB
United States Patent and Trademark Office issues OnDosis first patent April 11th
OnDosis, a MedTech company aiming to revolutionize the way patients take their medicines, announced the issuance by the USPTO of its 1st patent relating to the company’s device technology, a first in category Dosage Manager.
Emplicure and OnDosis announce partnership to develop better pain treatments
Emplicure AB och OnDosis AB utvärderar gemensamma utvecklingsmål för oral dosering av aktiva substanser baserade på bolagens respektive unika teknologier inom formulering och dosering.
TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and